138 related articles for article (PubMed ID: 25175952)
1. Sustained release of milrinone delivered via microparticles in a rodent model of myocardial infarction.
Al Kindi H; Paul A; You Z; Nepotchatykh O; Schwertani A; Prakash S; Shum-Tim D
J Thorac Cardiovasc Surg; 2014 Nov; 148(5):2316-23. PubMed ID: 25175952
[TBL] [Abstract][Full Text] [Related]
2. Cardioprotective activity of placental growth factor in a rat model of acute myocardial infarction: nanoparticle-based delivery versus direct myocardial injection.
Lu ZX; Mao LL; Lian F; He J; Zhang WT; Dai CY; Xue S; Lu WG; Zhu HS
BMC Cardiovasc Disord; 2014 Apr; 14():53. PubMed ID: 24742302
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic effects of milrinone with and without a bolus loading infusion.
Baruch L; Patacsil P; Hameed A; Pina I; Loh E
Am Heart J; 2001 Feb; 141(2):266-73. PubMed ID: 11174341
[TBL] [Abstract][Full Text] [Related]
4. A slow-releasing form of prostacyclin agonist (ONO1301SR) enhances endogenous secretion of multiple cardiotherapeutic cytokines and improves cardiac function in a rapid-pacing-induced model of canine heart failure.
Shirasaka T; Miyagawa S; Fukushima S; Saito A; Shiozaki M; Kawaguchi N; Matsuura N; Nakatani S; Sakai Y; Daimon T; Okita Y; Sawa Y
J Thorac Cardiovasc Surg; 2013 Aug; 146(2):413-21. PubMed ID: 23541854
[TBL] [Abstract][Full Text] [Related]
5. Preparation and in vitro evaluation of etoposide-loaded PLGA microspheres for pulmonary drug delivery.
Feng R; Zhang Z; Li Z; Huang G
Drug Deliv; 2014 May; 21(3):185-92. PubMed ID: 24107001
[TBL] [Abstract][Full Text] [Related]
6. Sustained release of VEGF through PLGA microparticles improves vasculogenesis and tissue remodeling in an acute myocardial ischemia-reperfusion model.
Formiga FR; Pelacho B; Garbayo E; Abizanda G; Gavira JJ; Simon-Yarza T; Mazo M; Tamayo E; Jauquicoa C; Ortiz-de-Solorzano C; Prósper F; Blanco-Prieto MJ
J Control Release; 2010 Oct; 147(1):30-7. PubMed ID: 20643169
[TBL] [Abstract][Full Text] [Related]
7. Milrinone in advanced heart failure: dose and therapeutic monitor outside intensive care unit.
Charisopoulou D; Leaver N; Banner NR
Angiology; 2014 Apr; 65(4):343-9. PubMed ID: 23620310
[TBL] [Abstract][Full Text] [Related]
8. Tracking the in vivo release of bioactive NRG from PLGA and PEG-PLGA microparticles in infarcted hearts.
Pascual-Gil S; Simón-Yarza T; Garbayo E; Prosper F; Blanco-Prieto MJ
J Control Release; 2015 Dec; 220(Pt A):388-396. PubMed ID: 26546270
[TBL] [Abstract][Full Text] [Related]
9. Unintended potential impact of perfect sink conditions on PLGA degradation in microparticles.
Klose D; Delplace C; Siepmann J
Int J Pharm; 2011 Feb; 404(1-2):75-82. PubMed ID: 21056644
[TBL] [Abstract][Full Text] [Related]
10. Intramyocardial injection of heart tissue-derived extracellular matrix improves postinfarction cardiac function in rats.
Dai W; Gerczuk P; Zhang Y; Smith L; Kopyov O; Kay GL; Jyrala AJ; Kloner RA
J Cardiovasc Pharmacol Ther; 2013 May; 18(3):270-9. PubMed ID: 23345062
[TBL] [Abstract][Full Text] [Related]
11. Biodegradation and heart retention of polymeric microparticles in a rat model of myocardial ischemia.
Formiga FR; Garbayo E; Díaz-Herráez P; Abizanda G; Simón-Yarza T; Tamayo E; Prósper F; Blanco-Prieto MJ
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):665-72. PubMed ID: 23523545
[TBL] [Abstract][Full Text] [Related]
12. Functionalized nanoparticles provide early cardioprotection after acute myocardial infarction.
Chang MY; Yang YJ; Chang CH; Tang AC; Liao WY; Cheng FY; Yeh CS; Lai JJ; Stayton PS; Hsieh PC
J Control Release; 2013 Sep; 170(2):287-94. PubMed ID: 23665256
[TBL] [Abstract][Full Text] [Related]
13. Preparation of ONO-1301-loaded poly(lactide-co-glycolide) microspheres and their effect on nerve conduction velocity.
Hazekawa M; Sakai Y; Yoshida M; Haraguchi T; Morisaki T; Uchida T
J Pharm Pharmacol; 2011 Mar; 63(3):362-8. PubMed ID: 21749383
[TBL] [Abstract][Full Text] [Related]
14. Preparation of bleomycin A2-PLGA microspheres and related in vitro and in vivo studies.
Zhang H; Gao Y; Lv W; Jiao C; Duan M; Liu H; Han B
J Pharm Sci; 2011 Jul; 100(7):2790-800. PubMed ID: 21344412
[TBL] [Abstract][Full Text] [Related]
15. Effects of the type of release medium on drug release from PLGA-based microparticles: experiment and theory.
Faisant N; Akiki J; Siepmann F; Benoit JP; Siepmann J
Int J Pharm; 2006 May; 314(2):189-97. PubMed ID: 16510257
[TBL] [Abstract][Full Text] [Related]
16. Elevation of plasma milrinone concentrations in stage D heart failure associated with renal dysfunction.
Cox ZL; Calcutt MW; Morrison TB; Akers WS; Davis MB; Lenihan DJ
J Cardiovasc Pharmacol Ther; 2013 Sep; 18(5):433-8. PubMed ID: 23695773
[TBL] [Abstract][Full Text] [Related]
17. Milrinone increases flow in coronary artery bypass grafts after cardiopulmonary bypass: a prospective, randomized, double-blind, placebo-controlled study.
Arbeus M; Axelsson B; Friberg O; Magnuson A; Bodin L; Hultman J
J Cardiothorac Vasc Anesth; 2009 Feb; 23(1):48-53. PubMed ID: 18834820
[TBL] [Abstract][Full Text] [Related]
18. PLGA:poloxamer blend micro- and nanoparticles as controlled release systems for synthetic proangiogenic factors.
Parajó Y; d'Angelo I; Horváth A; Vantus T; György K; Welle A; Garcia-Fuentes M; Alonso MJ
Eur J Pharm Sci; 2010 Dec; 41(5):644-9. PubMed ID: 20869438
[TBL] [Abstract][Full Text] [Related]
19. Silicon microfluidic flow focusing devices for the production of size-controlled PLGA based drug loaded microparticles.
Keohane K; Brennan D; Galvin P; Griffin BT
Int J Pharm; 2014 Jun; 467(1-2):60-9. PubMed ID: 24680950
[TBL] [Abstract][Full Text] [Related]
20. PLGA-based drug delivery systems: importance of the type of drug and device geometry.
Klose D; Siepmann F; Elkharraz K; Siepmann J
Int J Pharm; 2008 Apr; 354(1-2):95-103. PubMed ID: 18055140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
